Alligator Bioscience AB Reports Financial Results for Q3 2025 and Provides a Business Update

About this update from Alligator Bioscience Ab

LUND, SE / ACCESS Newswire / October 23, 2025 / Alligator Bioscience (Nasdaq Stockholm: ATORX)(STO:ATORX), a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs, today announced its interim results for the third quarter of 2025 and provided a business update. "This quarter represented several important steps forward for Alligator, both scientifically and strategically. The final 30-month OPTIMIZE-1 results confirm mitazalimab's unprecedented long-term survival benefit in pancreatic cancer and strengthen our conviction in its transformative potential. In parallel, we secured strong shareholder support through the successful TO 13 warrant program. These achievements position us well as we prepare for a Phase 3 trial and continue discussions with potential partners to fully realize the potential of mitazalimab and our broader pipeline." Søren Bregenholt, CEO of Alligator Bioscience BUSINESS UPDATE Mitazalimab HLX22 Partnering and innovation Company FINANCIAL SUMMARY FOR Q3 2025 AND YEAR-TO-DATE 2025 The financial summaries for the quarterly periods ending 30 September 2025 and 30 September 2024 are presented below. The financial summaries for the year-to-date periods ending 30 September 2025 and 30 September 2024 are presented below. The full report is attached as a PDF, and is also available on the company's website: https://alligatorbioscience.se/en/investors/financial-reports/ Alligator will host a webinar on Thursday, 23 October 2025, at 3 p.m. CEST/ 9 a.m. EDT for investors, analysts and media, where CEO Søren Bregenholt and CFO Johan Giléus will present and comment on the interim report, which will be followed by a Q&A session. The call will be held in English. Attendees need to register by following this link . For further information, please contact: Søren Bregenholt, CEO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 Johan Giléus, CFO E-mail: [email protected] Phone: +46 (0) 46 540 82 00 The information was submitted for publication, through the agency of the contact person set out above, at 08:00 a.m. CEST on 23 October 2025. About Alligator Bioscience Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. This validated approach promotes priming of tumor-specific T cells and reversing the immunosuppressive nature of the tumor microenvironment, with significant potential benefits for cancer patients across multiple types of cancer. The Company's lead drug candidate mitazalimab is currently ready for Phase 3 development, and has previously presented unprecedented survival data at 24-months follow up in first-line metastatic pancreatic cancer patients in the Phase 2 trial OPTIMIZE-1. Alligator is listed on Nasdaq Stockholm (ATORX) and headquartered in Lund, Sweden. For more information, please visit alligatorbioscience.com . Attachments 2025 Q3 EN SOURCE: Alligator Bioscience View the original press release on ACCESS Newswire

View stock analysis, news, and events for Alligator Bioscience Ab